SOX2 and cancer: Even if the notion of the cancer-stem cell remains controversial in oncology, it integrates multiple aspects: i) expression of cancer stemness markers (e.g. nanog, oct4, Sox2) (65); ii) cells with low cycling properties leading to the notion of dormant or quiescent cells; iii) intermediate and reversible profiles of drug sensitivity highlighted by persister cells (66, 67).